Canada allow emergency use of Tekmira's Ebola treatment
Send a link to a friend
[September 23, 2014]
(Reuters) - Canadian drugmaker
Tekmira Pharmaceuticals Corp said on Monday that U.S. and Canadian
regulators have authorized the use of its Ebola treatment in patients
who have confirmed or suspected infections from the deadly virus.
The Vancouver-based company said its treatment, TKM-Ebola, has been
administered to patients on an emergency basis and the repeat
infusions have been well-tolerated.
The drug was administered to Rick Sacra, a doctor who contracted the
virus in West Africa, and who has shown promising signs, the
Nebraska Medical Center said in a statement.
TKM-Ebola, an RNAi therapeutic, works by preventing the virus from
Expanded access protocols, authorized by the U.S. Food and Drug
Administration and Health Canada, allow drug developers to offer
experimental therapies to patients with serious diseases who cannot
participate in controlled clinical trials.
Tekmira Chief Executive Officer Mark Murray said the company's
supplies of the treatment are limited.
[to top of second column]
The company is developing TKM-Ebola under a contract with the U.S.
Department of Defense.
Tekmira's shares closed 15 percent up at C$26.01 in Toronto and up
17 percent at $23.61 on the Nasdaq.
(Reporting By Amrutha Penumudi in Bangalore and Rod Nickel in
Winnipeg, Manitoba; Editing by Simon Jennings and Jeffrey Benkoe)
[© 2014 Thomson Reuters. All rights
Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.